Previous Close | 1.1800 |
Open | 1.2000 |
Bid | 1.2100 x 800 |
Ask | 1.2600 x 800 |
Day's Range | 1.1900 - 1.2850 |
52 Week Range | 0.5900 - 11.1200 |
Volume | |
Avg. Volume | 1,786,544 |
Market Cap | 89.365M |
Beta (5Y Monthly) | 0.22 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2700 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for ACRS
Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.